HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Surgical Strategy of Pediatric Benign Sacral Tumors.

AbstractBACKGROUND:
Primary benign osseous tumors and tumor-like lesions at the sacrum are rare in the pediatric population and exact surgical strategy is still unclear. In this study, we evaluate the outcome for pediatric patients with benign tumors and tumor-like lesions at the sacrum who were receiving surgical treatment according to our proposed surgical strategy and classification.
METHODS:
We analyzed 49 pediatric patients with sacral benign tumors or tumor-like lesions aged 18 years and below from 2005 to 2018. There were 23 men and 26 women with a mean age of 14.0±3.8 years. Nineteen patients had giant cell tumors (GCTs), 9 aneurysmal bone cysts, 5 osteoblastomas, 5 neurogenic tumors, 3 hemangiomas, 3 teratomas, 2 Langerhans cell histiocytosis, 1 chondroblastoma, 1 fibrous dysplasia, and 1 GCT of tendon sheath. We proposed our surgical plan and surgical classification for pediatric patients with sacral benign tumors or tumor-like lesions.
RESULTS:
The mean follow-up duration was 6.2 years (range, 1.0 to 18.9 y). GCTs (39%, 19/49) and primary aneurysmal bone cysts (18%, 9/49) are the top 2 common histologic types. Preoperative selective arterial embolization (SAE) was performed in 12 cases and 24 patients received intraoperative aortic balloon occlusion (ABO) as the preoperative surgical plan. Furthermore, according to tumor location at the sacrum, we classified surgical excision of sacral benign tumors and tumor-like lesions into 3 types. Fourteen cases were classified as type I, 27 as type II, 3 as type III, and 5 patients with neurogenic tumors cannot be classified into this surgical classification. Ten patients had wound complications. Two had femoral artery thrombosis because of ABO application. One had mechanical failure. Rate of local recurrence was 16%. Seven patients with GCTs and 1 with neurogenic tumor had local recurrence. No patient died of disease at the last follow-up. For the assessment of neurological function, the rate of neurological dysfunction was 12% (6/49). Four cases had urinary incontinence, 3 fecal incontinence, and 3 had bowel obstruction. Next, univariate analysis for influence of preoperative SAE and intraoperative ABO on complications demonstrated that both of them exerted no significant influence on the occurrence of oncological and nononcological complications.
CONCLUSIONS:
The proposed surgical strategy can provide an excellent therapeutic effect for pediatric benign tumors and tumor-like lesions at the sacrum. Preoperative SAE and intraoperative ABO can safeguard pediatric patients with high vascularity of benign tumor at the sacrum during the operation.
LEVEL OF EVIDENCE:
Level IV.
AuthorsJun Wang, Zhiye Du, Rongli Yang, Xiaodong Tang, Taiqiang Yan, Wei Guo
JournalJournal of pediatric orthopedics (J Pediatr Orthop) Vol. 41 Issue 4 Pg. 227-235 (Apr 01 2021) ISSN: 1539-2570 [Electronic] United States
PMID33655901 (Publication Type: Journal Article)
CopyrightCopyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Topics
  • Adolescent
  • Aorta
  • Balloon Occlusion
  • Bone Cysts, Aneurysmal (pathology, surgery)
  • Child
  • Child, Preschool
  • Chondroblastoma (pathology, surgery)
  • Fecal Incontinence (etiology)
  • Female
  • Fibrous Dysplasia of Bone (surgery)
  • Follow-Up Studies
  • Giant Cell Tumor of Bone (pathology, surgery)
  • Hemangioma (surgery)
  • Histiocytosis, Langerhans-Cell (surgery)
  • Humans
  • Intestinal Obstruction (etiology)
  • Male
  • Neoplasm Recurrence, Local (pathology)
  • Nervous System Diseases (etiology)
  • Osteoblastoma (surgery)
  • Postoperative Complications (etiology)
  • Sacrum
  • Spinal Neoplasms (complications, pathology, surgery, therapy)
  • Teratoma (surgery)
  • Treatment Outcome
  • Urinary Incontinence (etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: